Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 3Neoplasms 2Colorectal Neoplasms 2Rectal Neoplasms 1Esophageal Neoplasms 1Epilepsy 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Lobular 1

Interventions

Cisplatin 90Fluorouracil 76Radiotherapy 63Paclitaxel 58Docetaxel 49Oxaliplatin 48Irinotecan 42Leucovorin 32Capecitabine 31Carboplatin 27Radiation 21Surgical Procedures, Operative 20Esophagectomy 20pembrolizumab 15Neoadjuvant Therapy 15Bevacizumab 15Cetuximab 13Drug Therapy 12Epirubicin 11Chemotherapy, Adjuvant 9S 1 (combination) 8Magnetic Resonance Spectroscopy 8Gemcitabine 8Trastuzumab 7Nivolumab 7Erlotinib Hydrochloride 7Surveys and Questionnaires 6Panitumumab 6Immunohistochemistry 6Chemoradiotherapy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Esophageal Neoplasms × Histocompatibility Testing × Clear all
NCT00319735 2016-04-28

Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas

Hoosier Cancer Research Network

Phase 2 Completed
41 enrolled 18 charts
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡